Biotech

All Articles

Analysts go into Avidity's DMD gain, showing nuances in records

.Avidity Biosciences pleased capitalists with stage 1/2 data in Duchenne muscular dystrophy (DMD) Fr...

Actinogen's cortisol blocker fails phase 2 depression study

.Actinogen Medical's cortisol blocker has missed the primary endpoint of a period 2 research in depr...

Bivictrix chooses going personal only technique to take ADC in to center

.Antibody-drug conjugates (ADCs) have gone to the facility of numerous a billion-dollar biobuck lice...

TPG tops up funds to $580M for financial investments all over lifestyle scientific researches

.Possession manager TPG, which has actually supported biotechs such as Sionna Therapeutics and also ...

Merck ceases period 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT program has actually endured one more problem. Months after shuttering a pha...

After a tough year, Exscientia folds into Recursion

.After a year specified through pipe cuts, the shift of its own chief executive officer and cutbacks...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Rehab was actually made an impression on good enough along with Harbour BioMed's bispecifi...

A nearer consider Brutal Biotech's Intense 15

.In this week's incident of "The Best Pipe," we're diving into Tough Biotech's annual Tough 15 exclu...

Lilly faces period 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration celebrating the approval of Alzheimer's ...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of notable management hirings, firings and ...